Skip to main content
SpringerLink
Log in

Ischemic Preconditioning Markedly Reduces the Severity of Ischemia and Reperfusion-Induced Arrhythmias: Role of Endogenous Myocardial Protective Substances

  • Chapter
Myocardial Preconditioning

Part of the book series: Medical Intelligence Unit ((MIU.LANDES))

Abstract

It could be argued that an even more important manifestation of ischemic tolerance resulting from ischemic preconditioning than the reduction in infarct size is the profound reduction in the severity of life-threatening ventricular arrhythmias that arise from myocardial ischemia and reperfusion. This is because myocardial ischemic injury can now be limited by a combination of early thrombolysis and appropriate drug therapy in those patients who have survived an acute coronary attack, whereas therapy to prevent the attack itself is less well established. The purpose of this chapter is to outline the evidence for the antiarrhythmic effect of preconditioning and to discuss the possible mechanisms of this protection with particular reference to studies in a canine model of ischemia and reperfusion.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wainwright CL, Parratt JR. Failure of cyclooxygenase inhibition to protect against arrhythmias induced by ischaemia and reperfusion; implications for the role of prostaglandins as endogenous myocardial protective substances. Cardiovasc Res 1991; 25: 93–100.

    Article  PubMed  CAS  Google Scholar 

  2. Podzuweit T, Binz K-H, Nennstiel P et al. The antiarrhythmic effects of myocardial ischemia. Relation to reperfusion arrhythmias. Cardiovasc Res 1989; 23: 81–90.

    Article  PubMed  CAS  Google Scholar 

  3. Parratt JR. Endogenous myocardial protective substances. Cardiovasc Res 1993; 27: 693–702.

    Article  PubMed  CAS  Google Scholar 

  4. Vegh A, Szekeres L, Parratt JR. Preconditioning: An early protective response to myocardial ischaemia. In: Parratt JR, ed. Myocardial Response to Acute Injury. London: Macmillan Press 1992: 110–127.

    Google Scholar 

  5. Parratt JR. The discovery of ischaemic preconditioning. Cardiovasc Res 1993; 27: 688.

    Article  PubMed  CAS  Google Scholar 

  6. Clark C, Foreman MI, Kane KA et al. Coronary artery ligation in anaesthetised rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods 1980; 3: 357–368.

    Article  PubMed  CAS  Google Scholar 

  7. Komori S, Parratt JR, Szekeres L et al. Preconditioning reduces the severity of ischaemia and reperfusion-induced arrhythmias in both anaesthetised rats and dogs. J Physiol 1990; 423: 16P (Abstract).

    Google Scholar 

  8. Komori S, Fujimaki S, Ijili H et al. Inhibitory effect of ischemic preconditioning on ischemic arrhythmias using a rat coronary artery ligation model. Japanese J Electrocardiol 1990; 10: 774–782.

    Article  Google Scholar 

  9. Vegh A, Komori S, Szekeres L et al. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 1992; 26: 487–495.

    Article  PubMed  CAS  Google Scholar 

  10. Kane KA, Parratt JR, Williams FM. An investigation into the characteristics of reperfusion-induced arrhythmias in the anaesthetised rat and their susceptibility to antiarrhythmic agents. Br J Pharmacol 1984; 82: 349–357.

    Article  PubMed  CAS  Google Scholar 

  11. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischaemic myocardium involve cyclooxygenase products. Cardiovasc Res 1990; 24: 1020–1023.

    Article  PubMed  CAS  Google Scholar 

  12. Wainwright CL, Parratt JR. Electrocardiographic and haemodynamic effects of myocardial preconditioning in pigs. J Mol Cell Cardiol 1990; 22 (Suppl III):PF65 (Abstract).

    Google Scholar 

  13. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium; reperfusioninduced arrhythmias. Am J Physiol 1987; 253: H1470 - H1476.

    PubMed  CAS  Google Scholar 

  14. Vegh A, Szekeres L, Udvary E. Effect of the blood supply to the normal noninfarcted myocardium on the incidence and severity of early post-occlusion arrhythmias in dogs. Basic Res Cardiol 1987; 82: 159–171.

    Article  PubMed  CAS  Google Scholar 

  15. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124–1136.

    Article  PubMed  CAS  Google Scholar 

  16. Vegh A, Szekeres L, Parratt JR. Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 1992; 107: 648–652.

    Article  PubMed  CAS  Google Scholar 

  17. Li GC, Vasquez JA, Gallagher KP et al. Myocardial protection with preconditioning. Circulation 1990; 82: 609–619.

    Article  PubMed  CAS  Google Scholar 

  18. Ovize M, Przyklenk K, Kloner RA. Partial coronary stenosis is sufficient and complete reperfusion is mandatory for preconditioning the canine heart. Circ Res 1992; 71: 1165–1173.

    Article  PubMed  CAS  Google Scholar 

  19. Koning MMG, Simonis LAJ, De Zeeuw S et al. Ischaemic preconditioning by partial occlusion without intermittent reperfusion. Cardiovasc Res 1994; 28: 1146–1151.

    Article  PubMed  CAS  Google Scholar 

  20. Przyklenk K, Bauer B, Ovize M et al. Regional ischemic preconditionings protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993; 87: 893–899.

    Article  PubMed  CAS  Google Scholar 

  21. McClanahan TB, Nao BS, Wolke LJ et al. Brief renal occlusion and reperfusion reduces myocardial infarct size in rabbits. FASEB J 1993; 7: A176 (Abstract).

    Google Scholar 

  22. Gho BC, Shoemaker RG, van der Lee C et al. Myocardial infarct size limitation in rat by transient renal ischemia. Circulation 1994; 90: I476 (Abstract).

    Google Scholar 

  23. Vegh A, Szekeres L, Parratt JR. Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning. Cardiovasc Res 1991; 25: 1051–1053.

    Article  PubMed  CAS  Google Scholar 

  24. Vegh A, Papp J Gy, Kasala K et al. Cardiac pacing in anaesthetized dogs preconditions the heart against arrhythmias when ischaemia is induced 24 h later. J Physiol 1994; 480: 89P (Abstract).

    Google Scholar 

  25. Kaszala K, Vegh A, Parratt JR et al. Time course of pacing induced preconditioning in dogs. J Molec Cell Cardiol 1995; 27: A145 (Abstract).

    Google Scholar 

  26. Koning MMG, Gho BCG, Van Klaarwater E et al. Rapid ventricular pacing produces myocardial protection by non-ischaemic activation of K’ATP channels. Circulation (in press).

    Google Scholar 

  27. Vegh A, Papp JGy, Parratt JR. Dexamethasone prevents the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing. Br J Pharmacol 1994; 113: 1081–1082.

    Article  PubMed  CAS  Google Scholar 

  28. Vegh A, Papp J Gy, Szekeres L et al. Antiarrhythmic effects of ischaemic preconditioning during the `second window of protection. ’ J Molec Cell Cardiol 1994; 26: A346 (Abstract).

    Google Scholar 

  29. Piacentini L, Wainwright CL, Parratt JR. The antiarrhythmic effect of preconditioning in rat isolated hearts does not involve AI receptors. Br J Pharmacol 1992; 107: 137P (Abstract).

    Google Scholar 

  30. Piacentini L, Wainwright CL, Parratt JR. The antiarrhythmic effect of ischaemic preconditioning in isolated rat hearts involves a pertussis toxin sensitive mechanism. Cardiovasc Res 1993; 27: 674–680.

    Article  PubMed  CAS  Google Scholar 

  31. Lawson CS, Coltart DJ, Hearse DJ. The antiarrhythmic action of ischaemic preconditioning in isolated blood perfused rat hearts does not involve functional Gi proteins. Cardiovasc Res 1993; 27: 681–687.

    Article  PubMed  CAS  Google Scholar 

  32. Lawson CS, Coltart DJ, Hearse DJ. `Dose-dependency’ and temporary characteristics of protection by ischaemic preconditioning against ischaemiainduced arrhythmias in rat hearts. J Mol Cell Cardiol 1993; 25: 1391–1402.

    Article  PubMed  CAS  Google Scholar 

  33. Parratt JR. Possibilities for the pharmacological exploitation of ischaemic preconditioning. J Mol Cell Cardiol 1995; 27: 991–1000.

    Article  PubMed  CAS  Google Scholar 

  34. Curtis MJ, Pugsley MK, Walker MJA. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res 1993; 27: 703–719.

    Article  PubMed  CAS  Google Scholar 

  35. Parratt JR. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sciences 1994; 15: 19–25.

    Article  CAS  Google Scholar 

  36. Vegh A, Papp JGy, Parratt JR. Pronounced antiarrhythmic effects of preconditioning in anaesthetised dogs: is adenosine involved? J Mol Cell Cardiol 1995; 27: 349–356.

    Article  PubMed  CAS  Google Scholar 

  37. Wainwright CL, Parratt JR. An antiarrhythmic effect of adenosine during myocardial ischaemia and reperfusion. Eur J Pharmac 1988; 145: 183–194.

    Article  CAS  Google Scholar 

  38. Parratt JR, Boachie-Ansah G, Kane K A et al. Is adenosine an endogenous antiarrhythmic agent under conditions of myocardial ischaemia? In: Paton DM ed. Adenosine and Adenine Nucleotides. London: Taylor and Francis, 1988: 157–166.

    Google Scholar 

  39. Vegh A, Papp J Gy, Parratt JR. Attenuation of the antiarrhythmic effects of ischaemic preconditioning by blockade of bradykinin B2 receptors. Br J Pharmacol 1994; 113: 1167–1172.

    Article  PubMed  CAS  Google Scholar 

  40. Parratt JR, Vegh A, Papp J Gy. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning-a brief review of the evidence. Canad J Physiol Pharmacol 1995; 73: 837–842.

    Article  CAS  Google Scholar 

  41. Parratt JR, Vegh A, Papp J Gy. Nitric oxide generation, following activation of bradykinin (B2) receptors, mediates the pronounced antiarrhythmic effects of ischaemic preconditioning in anaesthetised dogs. In: Moncada S ed. Biology of Nitric Oxide, Volume 3: Physiology and Clinical Aspects. London, Portland, 1994: 69–74.

    Google Scholar 

  42. Tohse N, Sperelakis N. cGMP inhibits the activity of single calcium channels in embryonic chick heart cells. Circ Res 1991; 69: 325–331.

    CAS  Google Scholar 

  43. Baumgarten CR, Linz W, Kunkel G et al. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993; 108: 293–295.

    Article  PubMed  CAS  Google Scholar 

  44. Koide A, Zeitlin IJ, Parratt JR. Kinin formation in ischaemic heart and aorta of anaesthetised rats. J Physiol 1993; 467: 125P (abstract).

    Google Scholar 

  45. Zeitlin IJ, Fagbemi SO, Parratt JR. Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity. Cardiovasc Res 1989; 23: 91–97.

    Article  PubMed  CAS  Google Scholar 

  46. Xiong W, Chen L-M, Woodley-Miller C et al. Identification, purification and localization of tissue kallikrein in rat heart. Biochem J 1990; 267: 639–646.

    PubMed  CAS  Google Scholar 

  47. Parratt JR. Cardioprotection by angiotensin converting enzyme inhibitors. Cardiovasc Res 1994; 28: 183–189.

    Article  PubMed  CAS  Google Scholar 

  48. Pahor M, Gambassi G, Carbonin P. Antiarrhythmic effects of ACE inhibitors: a matter of faith or reality? Cardiovasc Res 1994; 28: 173–182.

    Article  PubMed  CAS  Google Scholar 

  49. Vegh A, Szekeres L, Parratt JR. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetised dogs. Br J Pharmacol. 1991; 104: 294–295.

    Article  PubMed  CAS  Google Scholar 

  50. Vegh A, Papp J Gy, Szekeres L et al. Prevention by an inhibitor of the L-arginine-nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetised dogs. Br J Pharmacol 1993; 110: 18–19.

    Article  PubMed  CAS  Google Scholar 

  51. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994; 270: 681–689.

    PubMed  CAS  Google Scholar 

  52. Martin W, Villani GM, Jothianandan D et al. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by haemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985; 232: 708–716.

    PubMed  CAS  Google Scholar 

  53. Vegh A, Papp J Gy, Szekeres L et al. The local intracoronary administration of methylene blue prevents the pronounced antiarrhythmic effect of ischaemic preconditioning. Br J Pharmacol 1992; 107: 910–911.

    Article  PubMed  CAS  Google Scholar 

  54. Coker SJ, Parratt JR, Ledingham IM et al. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 1981; 291: 323–324.

    Article  PubMed  CAS  Google Scholar 

  55. Coker SJ, Parratt JR. Prostacyclin-antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK 36374 during coronary artery occlusion and reperfusion in anesthetised greyhouds. J Cardiovasc Pharmacol 1983; 5: 557–567.

    Article  PubMed  CAS  Google Scholar 

  56. Coker SJ, Parratt JR. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J Mol Cell Cardiol 1984; 16: 43–52.

    Article  PubMed  CAS  Google Scholar 

  57. Kis A, Vegh A, Papp JGy et al. Dual blockade of the cyclooxygenase and L-arginine-nitric oxide pathway prevents the antiarrhythmic effect of preconditioning. J Molec Cell Cardiol 1995; 27: A159 (Abstract).

    Google Scholar 

  58. Opie LH. Role of cyclic nucleotides in heart metabolism. Cardiovasc Res 1982; 16: 483–507.

    Article  PubMed  CAS  Google Scholar 

  59. Billman GE. Effect of carbachol and cyclic GMP on susceptibility to ventricular fibrillation. FASEB 1990; 4: 1668–1673.

    Google Scholar 

  60. Krause E-G, Ziegelhoffer A, Fedelsova M et al. Myocardial cyclic nucleotide levels following coronary artery ligation. Adv Cardiol 1978; 25: 119–129.

    PubMed  CAS  Google Scholar 

  61. Szekeres L, Szilvassy Z, Udvary E et al. 7–0X0 PGI2 induced late appearing and long lasting electrophysiological changes in the heart in situ of the rabbit, guinea-pig, dog and cat. J Mol Cell Cardiol 1989; 21: 545–554.

    Article  PubMed  CAS  Google Scholar 

  62. Szekeres L, Pataricza J, Szilvassy Z et al. Cardioprotection: endogenous protective mechanisms promoted by prostacyclin. Basic Res Cardiol 1992; 87: 215–221.

    Article  Google Scholar 

  63. Borchert G, Bartel S, Beyerdorfer I et al. Long lasting anti-adrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities. Molec Cell Biochem 1994; 137: 57–67.

    Article  Google Scholar 

  64. Parratt JR. Nitric oxide and cardiovascular dysfunction in sepsis and endotoxaemia—an introduction and an overview. In: Schlag G, Redl H, eds. Shock, Sepsis and Organ Failure, Fourth Bernard Wiggers Conference. Berlin: Springer 1995: 1–21.

    Chapter  Google Scholar 

  65. Parratt JR. The effect of adrenaline, noradrenaline, and propranolol on myocardial blood flow and metabolic heat production in monkeys and baboons. Cardiovasc Res 1969; 3: 306–314.

    Article  PubMed  CAS  Google Scholar 

  66. Parratt JR, Vegh A, Semeraro C et al. Beneficial effects of Z1046, a selective dopamine receptor agonist, during myocardial ischaemia. Br J Pharmacol 1995; 116: 286 P.

    Google Scholar 

  67. Parratt JR, Campbell C, Fagbemi O. Catecholamines and early post-infarction arrhythmias: the effects of alpha and beta-adrenoceptor blockade. In: Delius W, Gerlach E, Grobecker H et al, eds. Catecholamines and the Heart. Springer, Berlin 1981: 269–284.

    Chapter  Google Scholar 

  68. Vegh A, Papp J Gy, Parratt JR. Intracoronary noradrenaline suppresses ischaemia-induced arrhythmias in anaesthetised dogs. J Molec Cell Cardiol 1994; 26:Abstract 343.

    Google Scholar 

  69. Parratt JR, Vegh A. Pronounced antiarrhythmic effects of ischaemic preconditioning. Cardioscience 1994; 5: 9–18.

    PubMed  CAS  Google Scholar 

  70. Parratt JR, Vegh A, Papp J Gy. Pronounced antiarrhythmic effects of ischaemic preconditioning—are there possibilities for pharmacological exploitation ? Pharmacol Res 1995; 31: 225.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Agnes Vegh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James R. Parratt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Vegh, A., Parratt, J.R. (1996). Ischemic Preconditioning Markedly Reduces the Severity of Ischemia and Reperfusion-Induced Arrhythmias: Role of Endogenous Myocardial Protective Substances. In: Myocardial Preconditioning. Medical Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22206-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-22206-5_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-22208-9

  • Online ISBN: 978-3-662-22206-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation